GSK to decide on ChemoCentryx's RA candidate by year end
This article was originally published in Scrip
GlaxoSmithKline will decide by the end of the year whether it will exercise its option on ChemoCentryx's rheumatoid arthritis (RA) candidate CCX354 following publication of positive Phase IIa data, GSK told Scrip.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.